Epitestosterone is the 17a-epimer of testosterone and has been described as an anti-androgen, since it inhibits the effects produced by testosterone and dihydrotestosterone via the nuclear androgen receptor (nAR). However, epitestosterone also displays an effect which is similar to the non-classical effect of testosterone, depolarizing the membrane potential of Sertoli cells and inducing a rapid Ca 2þ uptake. This study aimed to investigate the effects of a treatment with epitestosterone on developmental parameters of immature rats. Animals were chemically castrated by using the gonadotropin-releasing hormone (GnRH) antagonist cetrorelix and then received a replacement of 7 days with epitestosterone or testosterone. Replacement with either epitestosterone or testosterone restored the anogenital distance (AGD) and testicular weight which had been reduced by chemical castration. The immunocontent of nAR and the nAR-immunoreactivity were reduced by epitestosterone treatment in the testis of both castrated and non-castrated animals. Furthermore, testosterone was unable of changing the membrane potential of Sertoli cells through its non-classical action in the group of animals castrated and replaced with epitestosterone. In conclusion, in relation to the level of protein expression of nAR epitestosterone acts as an anti-androgen. However, it acts in the same way as testosterone when genital development parameters are evaluated. Moreover, in castrated rats epitestosterone suppressed the non-classical response of testosterone, changing the pattern of testosterone signalling via a membrane mechanism in Sertoli cells.
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Introduction
Normal development of the testis during the postnatal and prepubertal periods results in a fertile adult life. It is known that androgens are important for testis development and the maintenance of spermatogenesis in adulthood. Although testosterone is capable of acting through both classical and non-classical mechanisms, most of the described effects of testosterone are associated with the classical mechanism, involving binding to the nuclear androgen receptor (nAR), by which it plays an important role in maintenance of the mature male reproductive tract and spermatogenesis (L€ osel and Wehling, 2003; Walker, 2010) . The lack of normal androgen activity during testicular development, both foetal and neonatal, can lead to failure of normal germ cell proliferation as a result of disruption of Sertoli cell (SC) function during the prepubertal period (Johnston et al., 2004; Sharpe, 2005) . At the end of the proliferation period, which occurs until postnatal day (pnd) 20 in rats, the SCs commence differentiation or maturation. This process can be accelerated in the case of increased nAR expression, resulting in a smaller SC population (Hazra et al., 2013; Lucas et al., 2014) . Nevertheless, several studies have reported a rapid signalling mechanism induced by testosterone, as reviewed in L€ osel and Wehling (2003) and Walker (2010) . This is a rapid response compared with the genomic effect, but stimulates several signalling pathways that may even stimulate transcriptional factors in the nucleus other than those stimulated by the nAR (Christiansen et al., 2008) . Moreover, it has been observed that testosterone has non-classical effects on the membrane of SCs from rats on pnd 3e4 despite the lack of nAR expression in these cells (da Rosa et al., 2015) . Testosterone also has a non-classical effect on the SC membrane of rats on pnd 15, 21, and 35 even in the presence of flutamide, an nAR inhibitor (de Castro et al., 2013) . The nonclassical effect of testosterone (25e1000 nM) consists of immediate depolarization of the SC membrane potential and an increase in 45 Ca 2þ uptake within 5 min (Von Ledebur et al., 2002) . This nonclassical action of testosterone in SCs activates an intracellular signalling pathway through an unidentified membrane receptor. A subsequent decrease in phosphatidylinositol 4,5 biphosphate (PIP2) reduces negative charges near the membranes and causes the closure of ATP-sensitive potassium (K þ ATP ) channels, depolarizing the membrane and opening the voltage-gated calcium channels (VGCC), thus resulting in a calcium influx (reviewed in Loss et al., 2011 Loss et al., , 2004 .
Epitestosterone (17a-hydroxy-4-androsten-3-one) is the natural 17a-epimer of testosterone. This steroid has been used as a natural internal standard for assessing androgen abuse in sports (St arka, 1993) . No interconversion of testosterone into epitestosterone was observed in the testes of rats or humans despite the fact that the testes are a source of endogenous epitestosterone in these species (Dehennin, 1993) . Besides this, little is known about the biological actions of epitestosterone. Some studies have shown an antiandrogenic effect of this steroid (Behre et al., 1995; Broulik and St arka, 1997; Lapcik et al., 1994; Nuck and Lucky, 1987; St arka et al., 1996) . It has been observed that the administration of epitestosterone to intact male mice decreases the weight of androgen-dependent structures such as the seminal vesicle, bone, and kidney, which are characterized as antiandrogen effects (St arka and Broulík, 2001 ). This steroid is capable of blocking androgenic action through inhibition of the enzyme 5a-reductase, which is responsible for the conversion of testosterone into dihydrotestosterone (Nuck and Lucky, 1987) . Epitestosterone seems to cause competitive inhibition in the nAR. The binding of epitestosterone to the nAR occurs with one-tenth the affinity of that of testosterone binding to this receptor (St arka et al., 1989) .
It is curious that the non-classical effects of epitestosterone on the SC membrane are similar to the effects of testosterone (da Rosa et al., 2015; de Castro et al., 2013) . It has been observed that epitestosterone, at similar doses, rapidly depolarizes the membrane potential of SCs in a similar way to testosterone and increases the calcium influx in testes (de Castro et al., 2013) . These effects were observed in rats on pnd 4, 15, 21, and 35, and the signalling pathway was also similar (da Rosa et al., 2015; de Castro et al., 2013) . Plasma levels of epitestosterone during the life span of humans were measured by Lapcik et al. (1995) and Havlíkov a et al. (2002) . These authors showed that epitestosterone prevails over testosterone during the immature period. The ratio of epitestosterone/testosterone during childhood is high and changes after puberty to the ratio 1:6 (epitestosterone:testosterone) (Havlíkov a et al., 2002; Lapcik et al., 1995) . The relative importance of these non-classical androgenic effects on SCs must be further considered for a better understanding of the complex process of the maintenance of immaturity during the development of the testis.
Cetrorelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that binds to the GnRH receptor, suppressing the releasing of gonadotropins, especially luteinizing hormone (LH), and subsequently androgens, resulting in chemical castration (Behre et al., 1992; Reissmann, 2000) . Immature rats treated with daily subcutaneous injection of cetrorelix (500 mg/kg body weight) showed suppressed levels of LH and follicle-stimulating hormone (FSH), castrated levels of testosterone, and decreased body and testis weight and SC number (Walczak-Jedrzejowska et al., 2011) . Furthermore, the pituitary GnRH receptor was downregulated in adult rats treated with cetrorelix (Halmos et al., 1996) . To ensure the efficacy of castration, we used the measure of anogenital distance (AGD). AGD has been used to evaluate androgen status and genital development in both rodents and humans. A shorter AGD is associated with lower testis weight and testosterone level, and abnormal genital development (Christiansen et al., 2008; Macleod et al., 2010; Scott et al., 2007) .
Thus, the aim of this study was to investigate the changes produced by epitestosterone treatment in prepubertal male rats normal or castrated. It was used chemical castration using the gonadotropin-releasing hormone (GnRH) antagonist cetrorelix, followed by 7 days of treatment with epitestosterone or testosterone. The effects on body growth and testes development, determined by the measurement of AGD, and testicular nAR expression and immunoreaction, were observed. In addition, we investigated the effect of treatment with epitestosterone on electrophysiological responses of Sertoli cells to testosterone in normal and chemically castrated rats.
Materials and methods

Animals
Male Wistar rats from pnd 7 to pnd 14 were used in this work. The animals were supplied by the animal reproduction facility CREAL-UFRGS (Centro de Reprodução e Experimentação de Animais de Laborat orio -UFRGS). The pups were kept with their nursing mothers in separated cages, 10 pups and one nursing mother per 
Solutions and drugs
Hank's Balanced Salt Solution (HBSS) buffer contained NaCl (145 mM), KCl (4.6 mM), NaHCO 3 (5 mM), MgCl 2 (1.6 mM), CaCl 2 $2H 2 O (1.6 mM), glucose (5 mM), and HEPES (10 mM) at pH 7.4. All reagents were purchased from Merck KGaA (Darmstadt, Alemanha) except for HEPES, which was acquired from SigmaeAldrich Co. (St. Louis, MO, USA). Cetrorelix (Serono Europe Ltd, London, UK), testosterone (98%), and epitestosterone (100%) from Sigma Aldrich Co (St. Louis, MO, USA) administered in the treatments were reconstituted in 2-hydroxypropyl-b-cyclodextrin 22% (Fluka, St. Louis, MO, USA). For the electrophysiological experiments, testosterone was diluted in ethanol (E. Merck, Darmstadt, Alemanha), and its concentration did not exceed 0.1% in the final solution. In order to avoid any unspecific effect caused by contamination, the purity of the stock of epitestosterone was confirmed using liquid chromatography tandem-mass spectrometry (LC-MS/MS) technique. No signal of contamination by testosterone was identified in epitestosterone stock ( Supplementary  Fig. S1 ).
Epitestosterone stock's purity analysis
We performed an LC-MS/MS based assay to evidence the EpiT (E5878, Sigma-Aldrich) purity. Since both standards (EpiT and testosterone) have the same MRM transitions we develop a methodology that ensures proper compounds separation. Testosterone retention time was 4.29 min and EpiT was 5.31 demonstrating suitable chromatographic separation allowing identification of both forms. No signal for testosterone was identified in EpiT standard injection ( Supplementary Fig. S1 ). The concentration of 200 ng/mL in acetonitrile was chosen due a high signal response allowing to identify contamination at trace levels.
2.2.1.1. LC-MS/MS. An Agilent 1200 LC system (Germany) coupled to Applied Biosystems API 500 triple quadrupole mass spectrometer (Toronto, Canada) was employed. The chromatographic separation was carried out on a XTerra C18 column (3.5 mm, 100 mm Â 2.1 mm; Waters, Milford, MA, USA) with guard column (Phenomenex, USA). The mobile phase gradient elution was water (A) and acetonitrile (B) both containing 0.1% of Formic Acid. The flow rate was 300 mL min À1 and a 4 min equilibrate time was applied. The gradient started with 40% of B remaining for 1 min, increasing to 95% in 2 min, kept for 6 min and decreasing to 40% in 9 min and maintained until 10 min. The column temperature was maintained at 40 C. The injection volume was 2 mL. Mass spectrometer resolution in multiple reactions monitoring (MRM) was unitary and dwell time applied was 150 ms for all transitions. The mass spectrometer was operated in positive electrospray ionization mode and precursor ions monitored were [MþH]þ (Supplementary  Table S1 ). Nitrogen was used as nebulizer gas, curtain gas, heater gas and collision gas (psi units). Collision gas (CAD) was set at 8 psi, nebulizer gas (GS1) and dryer Gas (GS2) were set at 55 psi. Curtain gas and temperature was set at 30 psi and 600 C, respectively. Electrospray capillary voltage was set at 5.5 kV.
Hormonal treatments
On pnd 7, male Wistar rats were randomized into five experimental groups each containing 10 to 12 animals. From pnd 7 to pnd 14, the rats were given daily intraperitoneal injections with (i) hormone solvent, 2-hydroxypropyl b-cyclodextrin 22% (control group e CTRL); (ii) 500 mg/kg/day of the GnRH antagonist cetrorelix (cetrorelix group e CET); (iii) 500 mg/kg/day of cetrorelix þ 2.5 mg/ kg/day of testosterone (cetrorelix plus testosterone group e CET þ T); (iv) 500 mg/kg/day of cetrorelix þ 2.5 mg/kg/day of epitestosterone (cetrorelix plus epitestosterone group e CET þ EpiT); or (v) 2.5 mg/kg of epitestosterone alone (epitestosterone group e EpiT). On pnd 14, the rats were culled by cervical dislocation, and the testes were immediately removed through abdominal incision for further analysis. The entire experiment was duplicated. These animal groups were used to perform the developmental analyses, nAR immunocontent and immunoreaction analyses, and electrophysiological studies.
On pnd 21, male Wistar rats were divided into two groups: control group (n ¼ 8), which received only the oily vehicle, and treatment group (n ¼ 8), which received 1 mg/kg/day of epitestosterone diluted in oily vehicle (Eyster et al., 2007; Phillip et al., 1992) . The animals were treated daily with subcutaneous injection for a period of 14 days. On pnd 35 the rats were culled by cervical dislocation, and the testes were immediately removed through abdominal incision and stored at À80 C. These testes were used for nAR gene expression analysis.
Measurement of body and testis weight and anogenital distance
The body weight and AGD were verified on the first (pnd 7) and last day (pnd 14) of treatment. The AGD is the distance (in mm) from the cranial edge of the anus to the base of the phallus of male animals (Scott et al., 2007) , and was measured using a digital caliper (Faithfull Tools, Kent, UK). The anogenital index (AGI) was calculated dividing AGD by the cube root of body weight (Gallavan et al., 1999) . After removal, the testes were weighed, and the weight served as an indicator of the impairment of testicular development due to the inhibition of gonadotropin release.
2.5. cDNA amplification and gene expression nAR gene expression was evaluated through reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA of the testicular tissue was extracted using TRIZOL (Invitrogen) and was reversetranscribed to cDNA using the Super-Script First-strand Synthesis System (Invitrogen™ Life Technologies) according to the manufacturer's instructions. PCR reactions were performed using nAR (target gene: sense: 5 0 -GACCTTGGATGGAGAACTACTCCG e3'; antisense: 5 0 e GGTTGGTTGTTGTCATGTCCGGC e3 0 ) and GAPDH (reference gene) primers. PCR conditions for nAR cDNA amplification were: 34 cycles at 94 C/1 min, followed by 56 C/1 min and 72 C/2 min. To prove effective amplification, PCR products were analysed by electrophoresis in 1% agarose gel. The capture of images was taken with a digital camera and analysed using ImageMaster software. The results generated by the analysis of nAR expression were compared to the reference gene expression (GAPDH) and were expressed as optical density index (ODI).
Western blot
To identify the immunocontent of nAR, testes were quickly dissected out and immediately frozen in liquid nitrogen, stored at À80 C prior to processing, and homogenized in lysis buffer.
Protein levels in the samples were quantified by the Bradford method (Bradford, 1976) . Forty mg of protein were separated on an 8% SDS-PAGE gel and transferred to nitrocellulose membranes (Amersham HybondeECL, GE Healthcare; São Paulo, Brazil). Membranes were blocked with 10% nonfat dry milk and then incubated overnight at 4 C with an anti-nAR antibody (1:1000, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:1000, Merck KGaA, Darmstadt, Alemanha) was used as a loading control. Immunoreactive bands were detected using enhanced chemiluminescence (Merck KGaA, Darmstadt, Alemanha) followed by exposure to autoradiography film (GE Healthcare Limited, Buckinghamshire, UK). Immunoblots were scanned and the intensity of the bands was quantified by densitometry using ImageJ software (U. S. National Institutes of Health, Bethesda, Maryland, USA). Data were expressed in relation to the control group.
Immunohistochemistry
In order to determine nAR immunoreactivity, testes were quickly dissected out and fixed in Bouin's solution for 4 h at room temperature. Tissues were dehydrated and embedded in paraffin wax following standard methods. Sections of 5 mm were obtained using a microtome (Micron Technology, Inc.) and mounted on glass slides. Immunohistochemical staining for nAR was performed as described previously (da Rosa et al., 2015) , using an anti-nAR polyclonal antibody (1:250, Santa Cruz Biotechnology, Inc.,Dallas, TX, USA). Sections from all experimental groups were run in parallel. For densitometry analysis, images were acquired using a digital camera connected to a Nikon Eclipse E-600 microscope (20Â objective -Nikon Corporation, Tokyo, Japan). Ten digital images from five distinct seminiferous tubules (cross-sections) were captured for each animal (n ¼ 4). All Sertoli cell nuclei contained in every tubule were analysed (about 20e40 nuclei per image). Thus, the Sertoli cells from 20 seminiferous tubules were analysed per experimental group. Using ImageJ software (U. S. National Institutes of Health, Bethesda, Maryland, USA), the images were first adjusted to equalize the background to a white colour. Then the mean intensity of Sertoli cell nuclei was determined after segmentation. The optical density was calculated using the following formula (De Fraga et al., 2004; Partata et al., 2002) :
where OD: optical density; I ("incident"): maximum intensity of incidental light; B ("black"): generated intensity when no light passes through the material; BG (x, y): ("background"): background intensity in a given pixel; IT (x, y): ("intensity") is the intensity of a given pixel of the analysed area.
The mean of the optical density values obtained for all cells in every tubule (cross-section) was used for statistical analyses.
Electrophysiology
For the electrophysiological experiments, the testes were decapsulated and carefully stretched using two tweezers, exposing three to 10 undisrupted seminiferous tubules. Then, the seminiferous tubules were fixed to the bottom of a superfusion chamber and incubated with 1 ml/min HBSS buffer, pH 7.4, at 34 C. A standard single-microelectrode recording was performed according to the method described by Von Ledebur et al. (2002) . The functional integrity of the tubular cells was preserved to maintain the environment as close as possible to its physiological conditions. The bulk of the recorded cells were characterized as SCs based on the microelectrode impalement depths, membrane potential stability, and membrane potential range, according to previously published data (da Rosa et al., 2015; Escott et al., 2013; Loss et al., 2011) . Microelectrode borosilicate pipettes were filled with KCl (3 M) and had a tip resistance of 15e25 MU. Our previous study showed that this tip resistance is appropriate for the impalement of cells of a similar size to SCs (Loss et al., 2011) . Furthermore, this tip diameter helps to eliminate the impalement of slim cells such as peritubular cells (Von Ledebur et al., 2002) . Intracellular recording was amplified using an intracellular amplifier Intra 767 WPI (World Precision Instruments Inc., Sarasota, FL, USA). Square current pulses of 0.5 nA, 0.5 Hz, and 250 ms duration were applied through the intracellular electrode to estimate membrane resistance using the S48 stimulator (Grass Instrument, West Warwick, RI, USA). An oscilloscope (Tektronix, 2 Channel Digital Oscilloscope TDS 210, Beaverton, OR, USA) and Wavestar Lite Version 1.0.10 software were used to record the variation in membrane potential. After the resting potential had stabilized for at least 2 min, a solution of testosterone (1 mM) was topically administered. We applied 2 mL of this testosterone solution (1 mM in 0.1% ethanol) in the superfusion chamber. As the volume of the chamber was 1 mL, testosterone solution was diluted by a factor of 500 times producing a final concentration almost equal to 2 nM. However, it is an approximated dose of testosterone reaching the cells since perfusion flow was kept opened (1 mL/min HBSS buffer) throughout the experiment. Each treatment was repeated at least five times with different cells from different animals. The variations in membrane potential were recorded and the results are presented as mean ± SEM.
Statistics
Data were analysed by one-way and repeated measures ANOVA with Bonferroni's post-test, linear regression analyses and Student's t-test. Data were expressed as mean ± SD. All analyses were carried out using GraphPad Prism version 6 (GraphPad Software, San Diego, California, USA, www.graphpad.com). Values of p < 0.05 were considered statistically significant.
Results
Developmental parameters
Body and testicular growth
The different treatments did not cause significant changes in the rats' body weight (Fig. 1A) .
The testicular weight was 22% lower in cetrorelix-treated animals compared with control animals. The castrated group with replacement of testosterone also had a lower testicular weight compared with the control group, but the difference was not as great (11% reduction). The cetrorelix plus epitestosterone group and the group treated with only epitestosterone did not differ from the control group (Fig. 1B and C) .
Anogenital distance (AGD) and anogenital index (AGI)
The effects of the GnRH antagonist cetrorelix and replacement with testosterone or epitestosterone were evaluated using the difference in AGD (DAGD) measured (in mm) at the beginning of treatment (pnd 7) and on the last day (pnd 14) (Fig. 2A) . The efficiency of castration was demonstrated by the significant reduction, by around 40%, in DAGD in the cetrorelix group compared with the control group. However, testosterone and epitestosterone replacement for one week restored AGD completely. Both the cetrorelix plus testosterone and cetrorelix plus epitestosterone groups were significantly different from the cetrorelix group. The epitestosterone alone group also differed from the cetrorelix group. Fig. 2B shows the AGI (calculated by dividing AGD by cubic root of body weight) measured on the first day (pnd 7) and the last day (pnd 14) of treatment. Using linear regression analyses, we observed that the slopes were significantly different from zero in all groups. The cetrorelix curve was very different from the control group, while in the cetrorelix plus testosterone and cetrorelix plus epitestosterone groups the deviation was similar to the control group.
Effect of different treatments on nAR
nAR gene expression
Twenty-one-day-old animals treated with epitestosterone (1 mg/kg/day) diluted in oily vehicle by subcutaneous injection for 14 days showed a significant reduction in nAR gene expression in the testicular tissue when compared with the control group (n ¼ 8), which only received the oily vehicle ( Fig. 3A and B) .
nAR immunocontent and immunoreactivity
The testicular immunocontent of nAR was evaluated by Western blotting. Rats treated with cetrorelix and epitestosterone (group CET þ EpiT) showed a significant reduction in the immunocontent of nAR compared to the control group. The other experimental treatments did not affect nAR immunocontent (Fig. 4) . In order to evaluate whether this reduction in nAR immunocontent produced by castration and replacement with EpiT, as observed by Western blot, was specific to Sertoli cells, we decided to run an immunohistochemistry analysis of nAR. A specific evaluation of nAR expression in Sertoli cells is very important, since our electrophysiological studies were performed on Sertoli cells. Following experimental treatment, nAR-immunoreactivity in the seminiferous tubules of 14-day-old animals was observed in the nuclei of 
Sertoli cells, as well as peritubular cells and Leydig cells. This is the same pattern of immunodetection reported in a previous paper for the testis of adult rats (da Rosa et al., 2015) . nAR immunoreactivity was weaker in all three experimental groups that received hormone administration. In rats treated with GnRH antagonist cetrorelix and replaced with testosterone, nAR immunoreactivity in Sertoli cells was significantly lower than in the control group ( Fig. 4A and B) . In animals in which epitestosterone was administered (castrated or not) nAR-immunoreactivity in Sertoli cells was significantly lower than in both the control and cetrorelix groups, as shown in Fig. 5. 3.3. Effect of non-classical testosterone activity on the membrane potential of Sertoli cells in whole seminiferous tubules
Effect of castration and epitestosterone treatment
The topical application of testosterone (1 mM) induced rapid depolarization of the membrane potential of Sertoli cells, with the membrane potential ranging from À46.06 ± 0.49 mV to À34.26 ± 4.64 mV at 180 s following application. This depolarization was significant ( a p<0.001) at 180 s after testosterone application, as shown in Fig. 6A . The GnRH antagonist cetrorelix-castrated rats showed a similar electrophysiological response to testosterone on the Sertoli cell membrane. The topical application of testosterone also resulted in rapid depolarization of the Sertoli cell membrane potential in the cetrorelix group (Fig. 6A) , with the membrane potential ranging from À40.97 ± 0.15 mV to À37.79 ± 1.38 mV ( b p < 0.05). This effect was significant 180 s after testosterone application and was similar to that observed in the control group. The topical application of testosterone induced rapid depolarization of the membrane potential of SCs from rats in the epitestosterone group (Fig. 6A) , with the membrane potential ranging from À48.60 ± 0.32 mV to 44.66 ± 1.26 at 180 s following application. This response was significant at 120 and 180 s ( b p < 0.05).
There was no significant difference in the response to testosterone between any of these experimental groups ( Fig. 6A and C) .
Testosterone and epitestosterone replacement
The topical application of testosterone produced rapid depolarization of the membrane potential of Sertoli cells from rats in the cetrorelix group (Fig. 6A and B) . The Sertoli cells from animals treated with replacement of testosterone (CET þ T) suffered depolarization induced by testosterone. However, this response was not significant at 180 s after testosterone application (Fig. 6B) , and not differ from the cetrorelix group at 180 s or from the control group (Fig. 6C) . Furthermore, the testosterone response in seminiferous tubules from rats in the cetrorelix plus epitestosterone group was completely abolished, and this response was significantly different from the cetrorelix group response and control at 180 s (Fig. 6B and C) .
Discussion
This work presents the influence of replacement with epitestosterone or testosterone in immature rats treated with a GnRH antagonist on developmental parameters such as body and testicular growth, AGD and nAR gene and protein expression. The effect of the different treatments on the electrophysiological response to testosterone on the membrane of Sertoli cells from whole seminiferous tubules was also studied. It was shown that both epitestosterone and testosterone replacement recovered the reduced AGD observed in the cetrorelix-castrated animals. However, only epitestosterone replacement was able to recover the testicular weight. Epitestosterone replacement in GnRH antagonist-castrated rats also reduced nAR immunocontent in total testis homogenates and nAR-immunoreactivity in Sertoli cells, as demonstrated by Western blot and immunohistochemistry experiments, respectively. In addition, the non-classical response to testosterone on the membrane of Sertoli cells was absent in rats from the group with the GnRH antagonist cetrorelix plus epitestosterone replacement.
Cetrorelix is a potent antagonist of GnRH, suppressing LH secretion and partially suppressing FSH secretion, and consequently decreasing androgen production by the testes (Halmos et al., 1996; Walczak-Jedrzejowska et al., 2011) . This effect is reversible after the discontinuation of treatment (WalczakJedrzejowska et al., 2011). Cetrorelix is viable for clinical purposes such as in vitro fertilization (Depalo et al., 2012) and prostate cancer (Rick et al., 2011) . The chronic administration of the GnRH antagonist cetrorelix produces downregulation of pituitary GnRH receptors and a decrease in the GnRH receptor mRNA (Kovacs et al., 2001 ). The dose used in this study, 500 mg/kg/day of cetrorelix, induced castration levels of testosterone (Walczak-Jedrzejowska et al., 2011) . Unfortunately, the lack of serum and testicular measurements of the levels of testosterone is a limitation of this paper and we are only inferring the existence of castration levels of this steroid based on the paper of Walczak-Jedrzejowska et al. (2011) which used the same conditions (doses and age of rats) of the present study. We observed that body weight was not affected by 7 days of treatment with cetrorelix (Fig. 1A) . Using the same dose, Walczak-Jedrzejowska et al. (2011) showed that 10 days of treatment with cetrorelix significantly reduced body development in rats. Testicular growth depends mainly on FSH (Petersen and Soder, 2006) . Cetrorelix reduced FSH level to 63% after 10 days of treatment (Walczak-Jedrzejowska et al., 2011) . We demonstrated a very significant decrease in the testis weight difference at the end of 7 days of treatment with cetrorelix (Fig. 1B) . Treatment with cetrorelix plus testosterone showed a minor decrease compared with the control group but cetrorelix with epitestosterone recovered testicular growth. Epitestosterone treatment alone did not change the weight of the testes. In the present study, it was demonstrated that epitestosterone had a better effect than testosterone in recovering the testicular weight reduction caused by cetrorelix treatment.
The AGD, the distance between the anus and the genitals, is normally used as a biomarker of foetal androgen action (van den Driesche et al., 2011). However, Mitchell et al. (2015) showed a reduction in AGD one week after castration in adult rats, demonstrating that AGD could be actively reduced in adulthood by a reduction in androgen levels. Therefore, we initially used AGD to certify that cetrorelix reduced androgen levels in treated animals. In fact, the cetrorelix group showed a significant reduction in AGD and AGI ( Fig. 2A and B) . This result confirmed the effect of cetrorelix as a GnRH antagonist and that at this dose (500 mg/kg/day) it induces castration levels of androgens produced by the testes. However, testosterone or epitestosterone treatment following cetrorelix recovered the AGD in a similar manner ( Fig. 2A and B) . A stimulatory effect of testosterone was expected as AGD is directly dependent on the level of this androgen (Mitchell et al., 2015; Scott et al., 2008) . The similarity of the effect of epitestosterone and testosterone in recovering AGD points to the involvement of something other than nAR in this parameter. Mitchell et al. (2015) and Scott et al. (2008) showed that in adult rats, flutamide, an antagonist of nAR, had no effect on AGD, while suppression of circulating testosterone induced a significant reduction in AGD.
As recently reviewed (Sharpe, 2005) it is known that foetal Sertoli cells do not express nAR. Its expression is weak in these cells in the early post-natal period, immediately after the neonatal testosterone surge. Subsequently the testosterone levels decline until the onset of puberty. In humans, the epitestosterone level in the pre-pubertal period is higher than or equal to the testosterone level. After puberty, the levels of testosterone increase above those of epitestosterone, reaching a ratio of 6:1, respectively, in adults . Besides the low level of testosterone, there is some evidence of the effect of androgen on the proliferation of Sertoli cells, but there is no consistent association between nAR expression and either cessation of Sertoli cell proliferation or terminal differentiation/maturation (Sharpe, 2005) .
Various hormones, such as FSH and thyroid hormone, regulate nAR expression during the proliferative period (Arambepola et al., 1998; Morais et al., 2013; Sharpe, 2005) . In male mice, epitestosterone administration affects the testis-hypophysis axis by reducing FSH and LH secretion (St arka et al., 1991) . Epitestosterone has also been described as an antiandrogen due to its demonstrated effects on the inhibition of 5-alpha-reductase, consequently reducing DHT formation from testosterone (Choi et al., 2001) . Also, epitestosterone seems to inhibit the growth of testosteronedependent tissues such as the prostate, seminal vesicles and kidneys (St arka, 2003; St arka et al., 1989) . Given these effects, we investigated the effect of treatment with epitestosterone on nAR expression. In this preliminary experiment, we found that epitestosterone significantly reduced nAR gene expression in the testis of 21-day-old rats treated with epitestosterone for 14 days (Fig. 3) . It also reduced the growth of several tissues (data not shown). Thereafter, we decided to conduct a more detailed study in 7-14-day-old rats, as described earlier (Figs. 1 and 2 ) in order to compare the effects of epitestosterone and testosterone in chemically castrated rats on nAR-immunoreactivity. We found that replacement with epitestosterone caused a reduction in the immunocontent of nAR as evaluated by Western blotting (Fig. 4) . In addition, the groups that received epitestosterone showed weaker nAR immunoreactivity in Sertoli cells compared with the cetrorelix and control groups (Fig. 5) . These results confirm the antiandrogenic effect of epitestosterone. Most studies related to the effects of testosterone on testes are based on its effects via the nuclear receptor, nAR (Lucas et al., 2014; Sharpe, 2005) . However, several authors have suggested the importance of the non-classical action of testosterone through another receptor (Loss et al., 2011; Walker, 2010) . Previous studies in our laboratory found similar rapid membrane effects of testosterone and epitestosterone on Sertoli cell from immature rats. Both steroids produced depolarization of the membrane potential of Sertoli cell and an increase in calcium uptake. Flutamide did not inhibit these non-classical effects of testosterone and epitestosterone (de Castro et al., 2013; Leite et al., 1999; Von Ledebur et al., 2002) . Additionally, this non-classical effect is present in Sertoli cells from neonatal rats lacking nAR. At this age, both testosterone and epitestosterone increased the 45 Ca 2þ uptake within 5 min, and testosterone produced rapid depolarization in the membrane of Sertoli cells from neonatal rats (da Rosa et al., 2015) . The testosterone depolarization in the membrane shown in Fig. 6A was similar to the effect described in previous studies using rats at pnd 12-15 (Cavalari et al., 2012; de Castro et al., 2013; Loss et al., 2004; Von Ledebur et al., 2002) . This effect involves a membrane mechanism through an unidentified receptor that activates phospholipase C, producing hydrolysis of phosphatidylinositol 4,5 biphosphate (PIP2) (Loss et al., 2004) . The lack of PIP2 reduces negative charges near membranes and causes the closure of K þ ATP channels and the opening of the VGCC, resulting in calcium influx (Loss et al., 2011 (Loss et al., , 2004 . The testosterone doses used in the electrophysiological experiments were based on previous works from our laboratory (Cavalari et al., 2012; de Castro et al., 2013; Loss et al., 2004; Von Ledebur et al., 2002) . The final concentration of testosterone in the superfusion chamber was almost equal to 2 nM and it was immediately washed out. We believe using this dose of testosterone (2 nM) there would be no risk of crossreactivity with other steroid receptors. However, we cannot exclude this possibility. Cetrorelix treatment did not change the pattern of this nonclassical testosterone response, besides a slight reduction similar to the group treated with epitestosterone alone. Surprisingly, a decrease in the non-classical testosterone response was observed in the castrated testosterone-replaced group, but there was a total lack of testosterone response in the castrated epitestosteronereplaced group.
The lack of LH and reduction in FSH levels in chemically castrated animals (Walczak-Jedrzejowska et al., 2011) may be induced by changes in the regulation of the unknown androgen membrane receptor in Sertoli cells. In the current study, epitestosterone and testosterone treatments seemed to cause downregulation of this membrane receptor in the chemically castrated animals. However, in the rats treated only with epitestosterone, the testosterone membrane response was similar to that in the castrated group, perhaps due to the described inhibitory effect of epitestosterone on LH and FSH release (St arka et al., 1991) . Even though epitestosterone showed an antiandrogenic effect on nAR expression, in castrated animals it also showed some effects similar to testosterone ones. It is known anti-androgens, as well as anti-estrogens could have a weak, but still positive effect, mainly in castrated rats. It may explain the reason why epitestosterone may have some positive effects, similar to the testosterone effects, in castrated animals (Roy et al., 2006) .
The relative importance of epitestosterone in the immature/ proliferative phase needs to be better understood. It is noteworthy that epitestosterone is important in testicular development, mainly through its actions on Sertoli cells. A better understanding of all factors that maintain Sertoli cell proliferation and those that trigger the maturation of these cells, which is fundamental for successful spermatogenesis and normal fertility, is also required. Our results suggest that epitestosterone plays an important role in maintaining Sertoli cell immaturity, through its effect on reducing nAR expression.
Conclusions
In this study, we showed that epitestosterone reduces nAR expression in immature rats. Furthermore, similarly to testosterone, epitestosterone recovered the AGD in immature rats castrated with GnRH-antagonist. This suggests that both hormones act through the same pathway on this developmental parameter, probably by a non-classical mechanism. Additionally, treatment with the GnRH antagonist plus epitestosterone reduced nAR expression in the testis and nAR-immunoreactivity in Sertoli cells and suppressed the non-classical testosterone response on the membrane of Sertoli cells.
